PharmiWeb: Dengue Vaccine Market Projected to Exceed USD 1.75 Billion by 2033, Growing at 13.2% CAGR | Marketresearch.biz Report
Marketresearch.biz reports that the Dengue Vaccine Market was valued at USD 524.2 million in 2023, It is expected to reach USD 1,755.8 million by 2033, with a CAGR of 13.2% during the forecast period ...
Dengue Vaccine Market Projected to Exceed USD 1.75 Billion by 2033, Growing at 13.2% CAGR | Marketresearch.biz Report
WHO fact sheet on dengue, providing information on symptoms, diagnostics and treatment, global burden, transmission, risk factors, prevention and control and WHO's work in this area.
Dengue fever is an infectious disease carried by mosquitoes and caused by any of four related dengue viruses. This disease used to be called "break-bone" fever because it sometimes causes severe joint and muscle pain that feels like bones are breaking. Health experts have known about dengue fever for more than 200 years. According to the Centers for Disease Control and Prevention, up to 400 ...
El dengue es una infección vírica transmitida por mosquitos. En las últimas décadas ha aumentado enormemente la incidencia de dengue en el mundo.
A Phase 2 clinical trial will test the safety and efficacy of an experimental treatment for dengue, a viral disease transmitted by mosquitoes.
Dengue is a self-limiting febrile illness with symptoms ranging from extremely mild (asymptomatic) to severe. Symptoms of dengue may be observed around 4–10 days after the bite of an infected mosquito. Common symptoms are like those of the flu, with patients experiencing: As the disease progresses, patients can also experience respiratory distress, bleeding from the nose and gums and rapid ...